No Data
No Data
Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating, Cuts Target Price to $15
Truist Financial Sticks to Their Buy Rating for Sutro Biopharma (STRO)
Express News | Sutro Biopharma Inc : Truist Securities Cuts Target Price to $15 From $18
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $8 to $17
Sutro Biopharma's Strong Financials and Clinical Progress Reinforce Buy Rating
Express News | Sutro Biopharma Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results. Additionally, HC Wainwright Reiterated a Buy Rating on the Stock
No Data